CCCC — C4 Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662579 ·
Last close
$4.06
Market Cap
$448.90M
52W High
$5.17
52W Low
$2.50
ADV30
3,572,135
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 6,152,000 | — | -27,785,000 | -25,129,000 | 328,861,000 | 61,274,000 | 94,614,000 |
| Dec 2025 | 11,016,000 | — | -23,145,000 | -20,486,000 | 359,075,000 | 74,603,000 | 102,488,000 |
| Sep 2025 | 11,230,000 | — | -23,679,000 | -32,166,000 | 265,488,000 | 58,809,000 | 111,080,000 |
| Jun 2025 | 6,463,000 | — | -28,501,000 | -26,020,000 | 296,527,000 | 78,157,000 | 122,463,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-95,353,000
Investing CF
$-21,573,000
Financing CF
$126,907,000
CapEx
$-486,000
Dividends Paid
—
Buybacks
$-238,000
EPS Diluted TTM
$-1.19
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-763,822,000
Inventory
—
Receivables
$2,883,000
ST Investments
$174,397,000
EBIT TTM
$-103,110,000
Pretax Income TTM
$-103,680,000
Interest Exp TTM
$0
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$34,861,000
EBITDA
$-101,203,000
Free Cash Flow
$-53,370,752
Enterprise Value
$297,109,376
Total Cash
$235,671,008
Total Debt
$58,447,000
Shares Out
110,567,222
Trailing EPS
$-1.10
Book Value
$2.25
ROE
-48.3%
ROA
-19.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,947,000 | -104,489,000 | -104,994,000 | 359,075,000 | 102,488,000 | — | -98,694,000 |
| Dec 2024 | 35,584,000 | -117,177,000 | -105,316,000 | 349,602,000 | 133,616,000 | — | -65,157,000 |
| Dec 2023 | 20,756,000 | -139,031,000 | -132,493,000 | 376,451,000 | 130,337,000 | — | -106,838,000 |
| Dec 2022 | 31,096,000 | -129,534,000 | -128,175,000 | 430,840,000 | 141,606,000 | — | -105,939,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.04
Max Pain — expiry 2027-01-15
max pain strike: $4.00 · spot: $4.06 · call oi: 6,750 · put oi: 172
Expected Move to 2027-01-15:
±$2.92
(71.92%) —
implied range
$1.14 –
$6.98
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARTV | Artiva Biotherapeutics, Inc. | $468.39M | $9.64 | — |
| AUTL | Autolus Therapeutics plc | $428.49M | $1.61 | — |
| CMPX | Compass Therapeutics, Inc. | $419.60M | $2.33 | — |
| XFOR | X4 Pharmaceuticals, Inc | $415.95M | $4.41 | — |
| ZURA | Zura Bio Ltd | $484.84M | $5.11 | — |
News headlines (Yahoo Finance, 1h cache)
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
2026-07-07 13:40 · Yahoo
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
2026-07-03 16:00 · Yahoo
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
2026-07-03 13:11 · Yahoo
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-06-18 13:40 · Yahoo
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
2026-06-11 11:46 · Yahoo
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret
2026-06-11 11:00 · Yahoo
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-01 16:00 · Yahoo
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
2026-06-01 13:40 · Yahoo
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
2026-05-25 17:00 · Yahoo
C4 Therapeutics to Participate in Upcoming Conferences
2026-05-20 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.